AGC Biologics to manufacture Teikoku Seiyaku rhMMP-7 drug substance for KTP-001 clinical trials
PUBT · 2d ago
Share
Listen to the news
- AGC Biologics, a subsidiary of AGC Inc., was selected by Teikoku Seiyaku to develop and manufacture KTP-001 (rhMMP-7) drug substance.
- Work covers microbial process development plus GMP production to supply clinical trials for a lumbar disc herniation therapy candidate.
- Cell bank creation will start in Heidelberg, Germany; the program will shift to Chiba, Japan for development and GMP manufacturing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605252000OMX_____CNEWS_EN_GNW9725558_en) on May 26, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending